Intra-Cellular Therapies Inc. (ITCI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.
